DIA ADSWG KOL Lecture Series
Update

August 12, 2015

Co-Chairs: Weili He, Li Chen
2015 KOL Lectures

- January 2015: Posch Martin (Medical University of Vienna, Austria) on Regulatory Issues in Adaptive Clinical Trial Designs
- February 2015: Jack Lee (MD Anderson) on Overview of Bayesian adaptive design: theory, tools, and implementation
- March 2015: Lanju Zhang (Abbvie) on Response adaptive randomization in clinical trials
- April 2015: Vlad Dragalin (J&J) on Considerations and optimizations of adaptive trial design in clinical development program
- May 2015: Olga Marchenko, Christy Nolan (Quintiles) on Implementing adaptive designs: Operational considerations, putting it all
- June 2015: Janet Wittes (Statistics Collaborative) on Adaptation Not By Design – When, If Ever, Can We (Should We) Do It?
2015 KOL Lectures (Cont’d)

- July 2015: Paul Gallo, Novartis, DMC issues
- August 2015: Nitin Patel, Cytel Inc., Dynamically Optimizing Budget Allocation for Phase 3 Drug Development Portfolios
- September 2015: Keaven Anderson, Merck, on an AD topic
- October 2015: Ivan Chan, Merck, A seamless Phase IIB/III adaptive outcome trial: design rationale and implementation challenges
- November: Qi Jiang, Amgen, Benefit-risk evaluation in adaptive design trials
- December 2015: Fanni Natanegara, Eli Lilly, on a Bayesian topic
KOL Lecture – Looking Forward

- KOL Schedule in 2016:
  - We have two confirmed speakers for 2016, and several potential topics as a result of the DIA ADSWG Best Practice subteam efforts
  - We will also reached out to the DIA Bayesian WG to include Bayesian topics as an outreach of the KOL series in 2016.
  - We will continue to solicit contributed presentations in 2016